NCT05471843
Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma No drug interventions treatment 1 / 2 recruiting NCT05645744
Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product. No drug interventions Not Available Not Available terminated NCT05360238
Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL No drug interventions treatment 1 / 2 terminated NCT05864742
Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma No drug interventions treatment 2 active_not_recruiting NCT05833763
A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure. No drug interventions treatment 2 recruiting NCT01389427
Escalating Doses of Torisel in Combination With Three Chemotherapies Regimens: R-CHOP, R-FC or R-DHA for Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL). No drug interventions treatment 1 / 2 completed NCT01921387
Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies treatment 1 / 2 completed NCT02568553
Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma treatment 1 active_not_recruiting NCT04635683
Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma treatment 1 withdrawn NCT06300528
Pemigatinib for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma or Marginal Zone Lymphoma treatment 2 not_yet_recruiting NCT03579888
CD19-Specific T Cells Post AlloSCT treatment 1 terminated NCT04205409
Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies treatment 2 active_not_recruiting NCT04578600
CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma treatment 1 active_not_recruiting NCT05025800
ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma treatment 1 / 2 recruiting NCT05249959
Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients. treatment 2 recruiting NCT03206970
Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL) treatment 2 completed NCT01955499
Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma treatment 1 active_not_recruiting NCT00723099
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer No drug interventions treatment 2 completed NCT04995536
CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL No drug interventions treatment 1 withdrawn NCT02736617
Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma treatment 2 completed NCT05453396
Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies treatment 2 recruiting NCT02051257
Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma No drug interventions treatment 1 active_not_recruiting NCT04007029
Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia treatment 1 recruiting NCT01381692
Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma No drug interventions treatment 1 / 2 completed NCT04659044
Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma No drug interventions treatment 2 active_not_recruiting NCT01880567
Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma No drug interventions treatment 2 active_not_recruiting NCT05910801
Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma No drug interventions treatment 2 recruiting NCT04484012
Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma No drug interventions treatment 2 recruiting NCT02420795
Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma No drug interventions treatment 1 / 2 terminated NCT01719250
Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma No drug interventions treatment 0 completed NCT06191887
B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies No drug interventions treatment 1 recruiting NCT02869633
Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant No drug interventions treatment 2 completed NCT02572453
Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL No drug interventions treatment 2 terminated NCT03219047
Patient-Derived Xenografts in Personalizing Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma No drug interventions treatment 0 completed NCT04047797
Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma No drug interventions treatment 2 active_not_recruiting NCT03946878
Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma No drug interventions treatment 2 active_not_recruiting NCT04990778
Venetoclax and Eprenetapopt for the Treatment of Relapsed of Refractory Mantle Cell Lymphoma No drug interventions treatment 2 withdrawn NCT03061188
Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma No drug interventions treatment 1 completed NCT03147885
Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma No drug interventions treatment 1 / 2 recruiting NCT04872413
Interrogating Biological Signaling Pathway Dysregulations and In Vitro Screening With Personalized Therapies in Relapsed or Refractory Mantle Cell Lymphoma, MCL MATCH Trial No drug interventions screening Not Available recruiting NCT01695941
Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma No drug interventions treatment 1 active_not_recruiting NCT01865617
Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia No drug interventions treatment 1 / 2 completed NCT03015896
Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma No drug interventions treatment 1 / 2 active_not_recruiting NCT04703686
Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy No drug interventions treatment 2 active_not_recruiting NCT02950220
Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma No drug interventions treatment 1 completed NCT06343376
Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies No drug interventions treatment 1 recruiting NCT03277729
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas No drug interventions treatment 1 / 2 active_not_recruiting NCT05936229
Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy No drug interventions prevention 1 / 2 withdrawn NCT03440567
Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma No drug interventions treatment 1 active_not_recruiting NCT04054167
Ultra Low Dose Radiation Delivered Before or After Chemotherapy-Free Targeted Therapy in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma No drug interventions treatment 2 recruiting NCT04939272
Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma No drug interventions treatment 1 / 2 active_not_recruiting NCT03479268
Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma No drug interventions treatment 1 active_not_recruiting NCT01897012
Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas No drug interventions treatment 1 completed NCT02489123
Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma No drug interventions treatment 2 terminated